Contact

Office: +31 242020020

info@screenpointmed.com

Technical support: +31 242020028

support@screenpointmed.com

Contact U.S.

Phone: 1-833-MammoAI (626-6624)

© 2019 by ScreenPoint Medical

 Management

ScreenPoint Medical has been founded by Nico Karssemeijer and Michael Brady, world leading experts in quantitative breast image analysis and computer aided detection. They have led research projects in the field for over twenty years and made important contributions to several current market leading breast imaging products.  They are also co-founders of Matakina Ltd. and guided the development Volpara, a vendor-neutral suite of software products for volumetric breast density analysis. Now, in ScreenPoint, Nico and Michael team up with Carl Evertsz, former CEO and co-founder of MeVis Medical Solutions and MeVis BreastCare, to develop with their colleagues a new generation of innovative products for improving the early detection of breast cancer.

CEO
Chairman
Non-Executive Director
Non-Executive Director
Non-Executive Director
COO
Head of R&D
Show More

Professor Nico Karssemeijer is a leading scientist in breast cancer imaging and has been one of the pioneers of computer-aided detection, playing a key role in its development and adoptation in breast cancer screening. He was closely involved in the development of the R2 ImageChecker, the first mammography CAD product. He also played an important role in implementing digital mammography in the European screening programs, by initiating and leading EU funded projects in which breast screening workstations were developed that are marketed today by major vendors. He is a Professor in the Department of Radiology, Radboud University, Nijmegen, The Netherlands, and he is co-founder of Matakina Ltd and of QView Medical Inc.  

Professor Sir Michael Brady FRS FMedSci FREng is a world leading scientist in computer vision, robotics, and medical image analysis.  He co-authored Mammographic Image Analysis (Kluwer 1999) with Ralph Highnam; the ideas introduced in this monograph - together with some later innovative developments by Nico Karssemeijer and colleagues - provided the basis for Volpara density.  As well, Brady has co-founded and steered several small high-growth technology companies to success.  In addition to Matakina, he is a Founder Director of: Perspectum Diagnostics, Mirada Medical, and Guidance Navigation; as well as being Chairman of:  Acuitas Medical, IRISS Medical, Colwiz,  and was until recently Deputy Chairman of Oxford Instruments plc.  

 

 

Dr. Carl Evertsz has extensive experience founding, leading, and growing innovative medical imaging companies. He actively led international business-, corporate- and R&D- developments, including an IPO, M&A and technology acquisitions. He also spearheaded the development and commercialization of multi-modality breast reading solutions, which significantly contributed to creating today’s de facto industry standards. Until 2012 Carl served as CEO of MeVis Medical Solutions AG, a publicly traded developer and provider of medical imaging software that he co-founded, and of MeVis BreastCare. He is managing director and owner of Pandushi, a private asset management and investment firm and serves in the supervisory board of Medis Medical Imaging Systems B.V.

 

Guido du Pree, M.Sc. has many years of experience in venturing, (digital) innovation and revenue growth in Medical Imaging, IVD, Healthcare Informatics and Genomics companies. He co-founded, built and managed the Philips Digital Pathology venture. Currently the venture is one of the spearheads in Philips Health growth ambitions with tens of millions of revenue and more than 300 people on the payroll. Two years ago, Guido founded an online market place for innovative Molecular/Genetic Diagnostic tests to make these tests easy available to cancer patients and their doctors. The first part of his career he spent in strategy consulting, M&A and fund raising for start-ups.

Anirudha has strong cross-functional expertise across general management, strategy, product & innovation management, and sales operations addressing customers across the world. In his function as vice president of New X-ray Markets at Siemens Healthineers, he is responsible for identifying and bringing new business opportunities in the X-ray products business line to the market. In his previous role, he was the head of the global value segment X-ray products where he drove the definition and development of a new mobile C-arm platform. He has also served as the head of CRM and sales analytics and as business manager for South Asia in prior positions. As a non-executive director at ScreenPoint Medical, he is jointly working towards improved breast cancer diagnosis using artificial intelligence.  

Pieter Kroese has extensive international experience in general, commercial and financial management, and has always been intensively involved in strategy development. He has a background in various industries, leading organisations of up to 400 people. He also developed hands-on entrepreneurial experience as co-founder of a technical startup company. During the last 7 years, Pieter has primarily been working with software development companies. He joined ScreenPoint in 2018 and is responsible for all business activities, driving the commercial focus and growth of the company, as well as assuming responsibility for operations and finance.

Dr. Gubern-Mérida obtained his joint Ph.D. degree in the field of medical imaging at the Diagnostic Image Analysis Group (DIAG) of the Radboud University Medical Center (Nijmegen, the Netherlands) and the University of Girona (Girona, Spain). His research focused on automated analysis of breast MRI, by developing image analysis and machine learning algorithms for breast cancer detection. As a post-doctoral researcher at DIAG, he expanded his research interest to other breast imaging modalities (mammography, digital breast tomosynthesis, and automated 3D breast ultrasound). In 2016, Dr. Gubern-Mérida joined ScreenPoint Medical, where he is currently the Head of Research and Development, leading the continuous evolution of the AI technology within the company.